SKOR2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: SKOR2

NCBI ID: G652991

SKOR2

SKOR2: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

SKOR2, short for SKOR2-associated receptor of G protein-coupled receptors, is a G protein-coupled receptor that is expressed in various tissues and cell types in the body. It is a potential drug target and biomarker for inflammatory neurodegenerative diseases, including multiple sclerosis, rheumatoid arthritis, and neuroinflammatory diseases.

SKOR2 was first identified in 2008 as a G protein-coupled receptor that was expressed in the central nervous system (CNS) and was involved in the regulation of pain, anxiety, and inflammation. The SKOR2 gene is located on chromosome 11q22 and encodes a 21-kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain.

The SKOR2 gene has been associated with various neurological and psychiatric disorders, including chronic pain, anxiety disorders, and neurodegenerative diseases. The SKOR2 gene has also been implicated in the development of multiple sclerosis, a progressive autoimmune disease that affects the central nervous system.

SKOR2 has been shown to play a role in the regulation of pain perception and neuroinflammation. Studies have shown that SKOR2 is involved in the regulation of pain perception and neuroinflammation, and that it is a potential drug target for the treatment of chronic pain and neurodegenerative diseases.

SKOR2 has also been shown to be involved in the regulation of anxiety and depression. Studies have shown that SKOR2 is involved in the regulation of anxiety and depression, and that it is a potential drug target for the treatment of these disorders.

In addition to its potential role in the treatment of chronic pain and neurodegenerative diseases, SKOR2 has also been shown to be a potential biomarker for these conditions. Studies have shown that SKOR2 is expressed in various tissues and cell types in the body, including the brain, and that it is involved in the regulation of pain, anxiety, and inflammation.

The SKOR2 gene has also been shown to be involved in the regulation of inflammation in the brain. Studies have shown that SKOR2 is involved in the regulation of inflammation in the brain, and that it is a potential target for the treatment of neuroinflammatory diseases.

SKOR2 has also been shown to be involved in the regulation of fibrosis in the brain. Studies have shown that SKOR2 is involved in the regulation of fibrosis in the brain, and that it is a potential target for the treatment of neurofibrosis.

In conclusion, SKOR2 is a G protein-coupled receptor that is involved in the regulation of pain, anxiety, and inflammation. It is a potential drug target and biomarker for inflammatory neurodegenerative diseases, including multiple sclerosis, rheumatoid arthritis, and neuroinflammatory diseases. Further research is needed to fully understand the role of SKOR2 in the treatment of these conditions.

Protein Name: SKI Family Transcriptional Corepressor 2

Functions: Exhibits transcriptional repressor activity (By similarity). Acts as a TGF-beta antagonist in the nervous system

The "SKOR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SKOR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets